Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera raised $275 million in its IPO ... Also on Thursday, Maze Therapeutics priced an upsized IPO at $16 a share, in the middle of a marketed range, according to a statement.

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...

Other hedge funds previously invested in Maze but not listed in the IPO filing as 5 percent owners: Casdin Capital, Deep Track Capital, and Woodline Partners. On Monday, Sionna Therapeutics said ...

Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...